Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Medicines and Healthcare products Regulatory Agency

MHRA warns patients about potential failure of Emerade adrenalin auto-injectors

Some Emerade adrenaline auto-injectors may fail to deliver a dose of adrenaline from the syringe owing to a blockage in the needle, the Medicines and Healthcare products Regulatory Agency (MHRA) has warned in a class 4 drug alert.

The issue was first detected in June 2018 during routine stability testing of the syringe component of Emerade; however, it was thought that it had the potential to affect just 1.5 in every 10,000 pens and was therefore a “rare event”.

Bausch and Lomb, which manufactures Emerade, has now said that the potential occurrence of needle blockage in batches on the market was higher than first estimated and could affect 2.3 in every 1,000 pens.

The alert applies to Emerade devices of all strengths (150 micrograms, 300 micrograms and 500 micrograms), but not to other marketed brands of adrenaline auto-injectors.

Lynne Regent, chief executive of the charity The Anaphylaxis Campaign, said it recognised this as a “very difficult time” for patients who carry Emerade auto-injectors.

“We would like to take this opportunity to remind all individuals who are prescribed an adrenaline auto-injector to always carry two devices at all times,” she said.

The MHRA said that it would not be recalling batches of Emerade and that the manufacturer had conducted “extensive investigations and has implemented corrective actions”.

Emerade manufactured with all the corrective processes is expected to be introduced into the market from mid-July 2019.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206807

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.